March 18th 2024
Silence Therapeutics' announcement of topline data from the ALPACAR-360 trial shows promising results for zerlasiran in reducing Lp(a) levels.
Experts' Perspectives: Top Issue Facing Cardiology in 2024
February 21st 2024This 2024 American Heart Month 2024 feature paints a picture describing the current state of cardiology by asking what the most prevalent and important issues facing the specialty are today from the perspective of 9 leading experts.
CLEAR Outcomes Analysis Finds Bempedoic Acid Reduces Total Cardiovascular Events by 20%
January 18th 2024In the CLEAR Outcomes trial, bempedoic acid was associated with a 20% reduction in relative risk for total cardiovascular events, with further analysis shining light on the effects of specific types of events.
Bempedoic Acid Proves Cardiovascular Benefit Across Glycemic Spectrum in New Analysis
August 30th 2023A prespecified analysis of the CLEAR Outcomes trial assessing outcomes according to glycemic status suggests bempedoic acid provided similar relative benefits across the glycemic spectrum, but the greatest absolute benefits were observed in patients with diabetes.
Statin Therapy Could Reduce Cardiovascular Events in People with HIV
July 24th 2023New data presented at the 12th International AIDS Society Conference on HIV Science suggests use of statin therapy in a primary prevention cohort of patients with HIV on antiretroviral therapy was associated with a 35% reduction in risk of cardiovascular events.
Study Suggests Bempedoic Acid Could Find Role in Primary Prevention
June 24th 2023An analysis of a primary prevention subgroup within the CLEAR Outcomes trial presented at ADA 2023 suggests use of bempedoic acid was associated with a 30% relative risk reduction for MACE among this patient population.
CLEAR Outcomes Data at ENDO 2023 Provides Further Insight into Effects of Bempedoic Acid
June 15th 2023An analysis of data from the CLEAR Outcomes trial presented at ENDO 2023 suggests use of the non-statin lipid-lowering agent provided cardiovascular risk reduction comparable to statin therapy for each 1.0 mmol/L reduction in LDL-C.
Combination Obicetrapib plus Ezetimibe Shows Promise for Dyslipidemia in Phase 2 Trial
June 14th 2023New data from the phase 2 ROSE2 trial is providing insight into the safety and tolerability, as well as LDL-lowering effects, of obicetrapib as an adjunct to high-intensity statin therapy as a monotherapy and in combination with ezetimibe.
Cardiology Month in Review: April 2023
May 2nd 2023Each month, our editorial staff compiles a recap of the top news in cardiology from the past month. Our April 2023 month in review features new data and documents related to heart failure management, recaps and forecasts of top regulatory decisions, and other top news!
Alirocumab Can Reduce Coronary Plaque Burden in Familial Hypercholesterolemia
April 5th 2023Data from the ARCHITECT trial detail the effects of alirocumab use on coronary plaque burden and characteristics in a cohort of patients with familial hypercholesterolemia but without atherosclerotic cardiovascular disease.
Failure to Reach LDL-C Target Increases Event Risk Nearly 50% in High-Risk Individuals
March 23rd 2023New research from the Family Heart Foundation indicates high-risk patients who fail to achieve LDL-C targets had a 49% greater rate of cardiovascular events than their counterparts who met LDL-C targets.
FDA Approves Evinacumab for HoFH in Children Aged 5-11 Years Old
March 22nd 2023The US FDA has approved an indication for evinacumab for use as an adjunct to other lipid-lowering therapies in children with homozygous familial hypercholesterolemia as young as 5 years old, which makes evinacumab the first ANGPTL3 inhibitor indicted for this patient population.
Bempedoic Acid Reduces Risk of MACE by 13%, But Proves No Benefit on Cardiovascular Death
March 4th 2023Results of the CLEAR Outcomes trial suggests adherence to bempedoic acid was associated with a 13% relative reduction in incidence of the trial's primary endpoint of 4-point MACE, but no benefit was observed for risk of cardiovascular death or all-cause mortality in the trial.
Despite Improved Screening and Rates of Dyslipidemia, Prescribing Not Yet at Optimal levels
January 13th 2023An analysis of NHANES data from 1999-2018 details the progress made with regard to cholesterol management on a population level but also provides insight into areas where room for improvement still exists.
Exposure to Statin Therapy Could Lower Risk of Brain Bleeds in Older Patients
December 9th 2022Data from an analysis of patients in Denmark provides an overview of the effects of statin therapy on risk of intracerebral hemorrhage, with insights into how this benefit may vary based on the location of the intracerebral hemorrhage.
CLEAR Outcomes: Bempedoic Acid Reduces Cardiovascular Events
December 7th 2022Almost 3 years after approval, Esperion's announcement of positive results from the CLEAR Outcomes trial indicate bempedoic acid is the first oral non-statin therapy to meet the MACE-4 primary endpoint included in the outcomes trial of the ATP citrate lyase inhibitor.
Extending Anticoagulation with Rivaroxaban After DVT Could Further Reduce Recurrent Thrombosis Risk
November 25th 2022Results of the RIDTS study suggest extending anticoagulation with rivaroxaban to 12 weeks as opposed to the traditional 6-week course could reduce recurrent venous thromboembolism in patients with symptomatic isolated DVT.